Spero Therapeutics (SPRO)
Develops SP001 while retaining economics linked to GSK-marketed Utebzi.
Something off on this page? Send us feedback.
Develops the in-licensed SP001 immunology candidate while retaining specified milestone and royalty economics linked to Utebzi, an oral antibiotic commercialized by GSK. Its operating focus shifted from an antibacterial portfolio to SP001 after legacy antibiotic programs were discontinued.
Develops SP001, an in-licensed anti-CD40L antibody for rare and high-unmet-need diseases. Its planned study targets IgG4-related disease, while Utebzi is an approved oral carbapenem commercialized by GSK in most licensed territories. The organization currently has a workforce of 25 employees.
Retains specified milestone and royalty economics tied to Utebzi after licensing tebipenem HBr to GSK. The earlier antibacterial portfolio narrowed when development of SPR206 and SPR720 ceased, concentrating the operating focus on SP001 and the GSK collaboration. GSK owns the IND and NDA for tebipenem HBr in the licensed territory.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $50.8M · Total debt $2.0M · Total assets $52.8M · Shareholders' equity $44.2M
- Revenue
- $0
- Operating income
- −$9.9M
- Net income
- −$9.6M
No dividends on record.
| Institutions55 holders · as of Mar 31, 2026 | 35.45% | 20.64M shares | |
| Insiders12 holders · as of Aug 6, 2026 | 8.49% | 4.94M shares | |
| Otherremainder | 56.06% | 32.65M shares |
58.23M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
GSK PLCInstitution | 15.78% | 9.19M | 13Fas of Mar 31, 2026 |
Pfizer IncInstitution | 4.06% | 2.36M | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 3.09% | 1.80M | 13Fas of Mar 31, 2026 |
Sath ShuklaInsiderofficer: CEO & President | 2.98% | 1.74M | Form 4filed Feb 5, 2025 ↗ |
Renaissance Technologies LLCInstitution | 2.04% | 1.19M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 4, 2026 | Esther Rajavelu | officer: See Remarks | −25,240 | $2.51 |
| Feb 6, 2026 | Timothy Keutzer | officer: Chief Operating Officer | −18,652 | $2.36 |
| Feb 6, 2026 | Esther Rajavelu | officer: See Remarks | −87,917 | $2.36 |
| Feb 4, 2026 | Timothy Keutzer | officer: Chief Operating Officer | −3,471 | $2.24 |
| Feb 3, 2026 | Timothy Keutzer | officer: Chief Operating Officer | −24,224 | $2.14 |
- Amgen
Approved IgG4-RD treatment with B-cell depletion
- Sanofi (ADR)
Late-stage developer of the anti-CD40L antibody frexalimab
- United Community Banks
Phase 3 developer of the CD40L inhibitor dapirolizumab pegol
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Spero Therapeutics | $1.22 | +1.67% | $70.6M | 11.1 | — | 1.6 | −100.0% |
| Amgen | $442.50 | −0.08% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Sanofi (ADR) | $44.57 | +0.24% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| United Community Banks | $35.40 | +1.20% | $4.19B | 11.5 | 11.5 | 2.7 | +9.8% |
| Median | 27.5 | 15.2 | 2.7 | +9.8% |